Ranexa MERLIN Trial Could Support First-Line Angina, Acute Coronary Syndrome Indications

CV Therapeutics says 5,500-patient Ranexa outcomes trial in ACS patients expected to begin in fourth quarter under a special protocol assessment with FDA. An absence of a trend towards death or arrhythmia would be sufficient for first-line chronic angina claim, firm says.